Chargement en cours...
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
As the first cardiovascular (CV) outcome trial of a glucose-lowering agent to demonstrate a reduction in the risk of CV events in patients with type 2 diabetes mellitus (T2DM), the EMPAgliflozin Removal of Excess Glucose: Cardiovascular OUTCOME Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-...
Enregistré dans:
| Publié dans: | Diabetes Metab Syndr Obes |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove Medical Press
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5905845/ https://ncbi.nlm.nih.gov/pubmed/29695924 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S154602 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|